Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Lemborexant on Sleep Latency in Insomnia Disorder
NCT02350309Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lemborexant in insomnia disorder (4 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Mean Change From Baseline in the Average Sleep Onset Latency From Modified-Multiple Sleep Latency Test. Started Dec 2014; status: completed.
02
Drugs
lemborexant
03
Conditions
insomnia disorder
Beyond the preview
Go deeper on NCT02350309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02350309.